{
  "trial_id": "NCT04470440",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "age",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "histologically confirmed locally advanced stage (IIIB) or metastatic (IV) non-small cell lung cancer with disease progression",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "treated with Nivolumab as second or more therapeutic line",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "in the oncologic department university hospital of Brest",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "primary tumor was not from bronchopulmonary origin",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "history of total thyroidectomy and/or having previously treated with levothyroxine and/or having a thyroid dysfunction previously to the introduction of Nivolumab",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "no thyroid monitoring during Nivolumab treatment, and data were missing",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "opposition to participate in the study",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has Hashimoto's thyroiditis, but was treated with Levothyroxine and showed improvement. No history of total thyroidectomy or previous thyroid dysfunction.",
  "_meta": {
    "topic_id": "30",
    "trial_id": "NCT04470440",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}